Dr. Michel Lebel PhD is a full professor in the Department of Molecular Biology, Medical Biochemistry, and Pathology at Laval University. Dr. Lebel obtained his PhD from Université de Montréal and completed post-doctoral studies in the Department of Genetics at Harvard Medical School. He has been an independent investigator since 2000 at the Centre de Recherche du CHU de Québec. His research focuses on deciphering the molecular and cellular events leading to premature aging in a mouse model of Werner syndrome. Press releases on the results of his work have been published by the Science Daily news, the National Post, Medical News Today, the Montreal Gazette, and the Nutraceuticals World online magazine. He was interviewed by the CBC radio (107,7 FM) on January 11th, 2010 and by the Journal de Québec on September 30th, 2012 (Le vieillissement, plus qu’une affaire de gènes).
Since the middle of the last century, improvements in healthcare have increased human life expectancy. However, we are now facing the new challenge and paradox of an older population with increased longevity, but often still with many years of poor health or disability ahead of them. A better understanding of the mechanisms leading to the decline in function with age would provide new predictive biomarkers and potential therapeutic targets. It is now clear that each person’s genetic code has a significant influence on the aging process. The main goal of Dr. Lebel’s research is to understand why a slight modification of certain genes precipitates the onset of age-related diseases, and to identify key biological factors leading to the onset of these diseases. In addition, using cutting-edge technologies, his team is working to understand how vitamin C and other natural products may prevent age-related diseases in humans. To do this, Dr. Lebel is studying a mouse model of a human genetic disorder called Werner syndrome, characterized by premature aging in affected patients. Finally, Dr. Lebel’s laboratory is also working to identify key proteins in the blood that would help diagnose cancer more quickly in patients.
2705, boulevard Laurier
Canada G1V 4G2
Data not available
Metabolic and Phenotypic Differences between Mice Producing a Werner Syndrome Helicase Mutant Protein and Wrn Null Mice.Journal Article
PLoS ONE, 10 (10), pp. e0140292, 2015.
Expression profile of Caenorhabditis elegans mutant for the Werner syndrome gene ortholog reveals the impact of vitamin C on development to increase life span.Journal Article
BMC Genomics, 15 , pp. 940, 2014.
Liver aging and pseudocapillarization in a Werner syndrome mouse model.Journal Article
J Gerontol A Biol Sci Med Sci, 69 (9), pp. 1076-86, 2014, ISSN: 1079-5006.
Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis.Journal Article
BMC Cancer, 13 , pp. 303, 2013.
Les longs ARNs non-codants: régulateurs clés des maladies liées au vieillissement?Journal Article
MSA : Médecine Sciences Amérique, 2 (3), pp. 1-13, 2013.
Down regulation of miR-124 in both Werner syndrome DNA helicase mutant mice and mutant Caenorhabditis elegans wrn-1 reveals the importance of this microRNA in accelerated aging.Journal Article
Aging (Albany NY), 4 (9), pp. 636-47, 2012, ISSN: 1945-4589.
The Werner syndrome gene product (WRN): a repressor of hypoxia-inducible factor-1 activity.Journal Article
Exp Cell Res, 318 (14), pp. 1620-32, 2012, ISSN: 0014-4827.
Drugs, nutrients, and phytoactive principles improving the health span of rodent models of human age-related diseases.Journal Article
J Gerontol A Biol Sci Med Sci, 67 (2), pp. 140-51, 2012, ISSN: 1079-5006.
Poly(ADP) Ribose Polymerase at the Interface of DNA Damage Signaling and DNA RepairBook Chapter
L, Panasci; R, Aloyz; M, Alaoui-Jamali (Ed.): Advances in DNA Repair in Cancer Therapy, pp. 167-186, New York, NY, Springer, 2012, ISBN: 9781461447412.
NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines.Journal Article
Mol Cancer, 10 , pp. 145, 2011.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Cibler l’instabilité génomique en tant que vulnérabilité essentielle du cancer de l’ovaire, Subvention, Fonds de recherche du Québec - Santé, ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer, from 2018-05-01 to 2021-04-30
Recently finished projects
- Soutien au projet de recherche dans l'axe endocrinologie et néphrologie, Subvention, Fondation du CHU de Québec, from 2020-02-19 to 2020-03-31